GSRX Industries Inc. (GSRX)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2022 | - USD | 0.0% |
| 2021 | - USD | 0.0% |
| 2020 | - USD | -100.0% |
| 2019 | 3.58 Million USD | 394.86% |
| 2018 | 724.5 Thousand USD | 224.14% |
| 2017 | 223.51 Thousand USD | -64.07% |
| 2016 | 622.02 Thousand USD | 16.49% |
| 2015 | 533.98 Thousand USD | 18.45% |
| 2014 | 450.8 Thousand USD | 21.44% |
| 2013 | 371.22 Thousand USD | 25.51% |
| 2012 | 295.76 Thousand USD | 30.96% |
| 2011 | 225.83 Thousand USD | 43.38% |
| 2010 | 157.51 Thousand USD | 67.22% |
| 2009 | 94.19 Thousand USD | 170.55% |
| 2008 | 34.81 Thousand USD | 365.12% |
| 2007 | 7485.00 USD | 648.5% |
| 2006 | 1000.00 USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2022 FY | - USD | 0.0% |
| 2021 FY | - USD | 0.0% |
| 2020 Q2 | 2.21 Million USD | -34.77% |
| 2020 FY | - USD | -100.0% |
| 2020 Q3 | 3 Million USD | 35.32% |
| 2020 Q1 | 3.4 Million USD | -5.11% |
| 2019 FY | 3.58 Million USD | 394.86% |
| 2019 Q2 | 3.46 Million USD | -54.72% |
| 2019 Q1 | 7.66 Million USD | 957.55% |
| 2019 Q3 | 3.56 Million USD | 2.63% |
| 2019 Q4 | 3.58 Million USD | 0.7% |
| 2018 Q4 | 724.5 Thousand USD | 33.15% |
| 2018 FY | 724.5 Thousand USD | 224.14% |
| 2018 Q2 | 248.82 Thousand USD | 326.16% |
| 2018 Q3 | 544.11 Thousand USD | 118.67% |
| 2018 Q1 | 58.38 Thousand USD | -73.88% |
| 2017 Q2 | 5750.00 USD | -99.11% |
| 2017 Q4 | 223.51 Thousand USD | 781.86% |
| 2017 FY | 223.51 Thousand USD | -64.07% |
| 2017 Q1 | 646.43 Thousand USD | 3.92% |
| 2017 Q3 | 25.34 Thousand USD | 340.8% |
| 2016 Q4 | 622.02 Thousand USD | 3.68% |
| 2016 Q2 | 579.08 Thousand USD | 3.86% |
| 2016 FY | 622.02 Thousand USD | 16.49% |
| 2016 Q1 | 557.58 Thousand USD | 4.42% |
| 2016 Q3 | 599.93 Thousand USD | 3.6% |
| 2015 Q4 | 533.98 Thousand USD | 13.92% |
| 2015 FY | 533.98 Thousand USD | 18.45% |
| 2015 Q3 | 468.74 Thousand USD | -4.92% |
| 2015 Q2 | 493.02 Thousand USD | 4.16% |
| 2015 Q1 | 473.31 Thousand USD | 4.99% |
| 2014 Q2 | 411.97 Thousand USD | 4.95% |
| 2014 Q1 | 392.55 Thousand USD | 5.75% |
| 2014 FY | 450.8 Thousand USD | 21.44% |
| 2014 Q4 | 450.8 Thousand USD | 4.59% |
| 2014 Q3 | 431.03 Thousand USD | 4.62% |
| 2013 Q1 | 317.24 Thousand USD | 7.26% |
| 2013 Q2 | 334.87 Thousand USD | 5.56% |
| 2013 Q4 | 371.22 Thousand USD | 3.9% |
| 2013 FY | 371.22 Thousand USD | 25.51% |
| 2013 Q3 | 357.29 Thousand USD | 6.7% |
| 2012 Q2 | 260.23 Thousand USD | 5.93% |
| 2012 FY | 295.76 Thousand USD | 30.96% |
| 2012 Q4 | 295.76 Thousand USD | 5.94% |
| 2012 Q3 | 279.17 Thousand USD | 7.28% |
| 2012 Q1 | 245.66 Thousand USD | 8.78% |
| 2011 Q1 | 177.89 Thousand USD | 12.94% |
| 2011 Q4 | 225.83 Thousand USD | 8.49% |
| 2011 Q3 | 208.17 Thousand USD | 7.82% |
| 2011 Q2 | 193.07 Thousand USD | 8.53% |
| 2011 FY | 225.83 Thousand USD | 43.38% |
| 2010 Q1 | 114.16 Thousand USD | 21.21% |
| 2010 Q3 | 142.49 Thousand USD | 11.1% |
| 2010 FY | 157.51 Thousand USD | 67.22% |
| 2010 Q4 | 157.51 Thousand USD | 10.54% |
| 2010 Q2 | 128.25 Thousand USD | 12.34% |
| 2009 Q2 | 66.43 Thousand USD | 25.92% |
| 2009 FY | 94.19 Thousand USD | 170.55% |
| 2009 Q4 | 94.19 Thousand USD | 16.67% |
| 2009 Q3 | 80.73 Thousand USD | 21.52% |
| 2009 Q1 | 52.76 Thousand USD | 51.55% |
| 2008 FY | 34.81 Thousand USD | 365.12% |
| 2008 Q3 | 21.71 Thousand USD | 166.9% |
| 2008 Q4 | 34.81 Thousand USD | 60.32% |
| 2008 Q2 | 8136.00 USD | -57.06% |
| 2008 Q1 | 18.94 Thousand USD | 153.12% |
| 2007 FY | 7485.00 USD | 648.5% |
| 2007 Q3 | 3700.00 USD | -54.55% |
| 2007 Q4 | 7485.00 USD | 102.3% |
| 2007 Q1 | 6000.00 USD | 0.0% |
| 2007 Q2 | 8140.00 USD | 35.67% |
| 2006 FY | 1000.00 USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| BioQuest Corp. | 632.89 Thousand USD | 100.0% |
| High Sierra Technologies, Inc. | 611.78 Thousand USD | 100.0% |
| Instadose Pharma Corp. | - USD | NaN% |